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Background: Frontotemporal dementia (FTD) is one of the most frequent dementia types in 
patients under 65 years of age. Currently, no therapy can effectively improve the cognitive defi-
cits associated with FTD. Repetitive transcranial magnetic stimulation (rTMS) is a noninvasive 
method of inducing brain plasticity with therapeutic potential in neurodegenerative diseases. 
The purpose of this study was to evaluate the effect of rTMS on cognitive, behavioral, and 
emotional function in FTD. 
Methods: Nine patients (seven women, four men, mean age 61.7±10.1 years) with the behavioral 
variant of FTD, one with nonfluent/agrammatic variant primary progressive aphasia, and one 
with progressive nonfluent aphasia (subtypes of FTD) underwent 10 daily sessions of 10 Hz 
rTMS over the bilateral dorsolateral prefrontal cortex. Cognitive and behavioral assessments 
were administered before and after therapy. 
Results: After rTMS, the Montreal Cognitive Assessment and letter and digit cancellation test 
scores, as well as reading time and error number in the Stroop test improved. The caregivers’ 
impression of the daily functioning of patients improved in the Frontal Behavioral Inventory 
scores. These changes were not paralleled by an improvement of mood. 
Conclusion: The results indicate that rTMS may improve the cognitive performance of patients 
with FTD and warrant sham-controlled trials.
Keywords: frontotemporal dementia, repetitive transcranial magnetic stimulation, Montreal 
Cognitive Assessment
Introduction
Frontotemporal dementia (FTD) is one of the most common types of dementia among 
people under 65 years of age.1 The neurodegenerative process primarily involves 
the frontal and temporal lobes, with various predominance. Currently, three clinical 
variants have been distinguished: behavioral variant frontotemporal dementia (bvFTD), 
nonfluent/agrammatic variant primary progressive aphasia (nfvPPA), and semantic 
variant-primary progressive aphasia (SV-PPA).2 Death usually occurs 8 years after 
clinical onset. There is no disease-modifying treatment. Some alleviation of behavioral 
and other psychiatric symptoms may be achieved with selective serotonin reuptake 
inhibitors and with atypical antipsychotics.3 However, there is no established therapy 
for cognitive deficits and none of the controlled trials conducted thus far has shown 
significant benefit.4,5 Two open studies showed improvements in language function 
after transcranial direct current stimulation (tDCS) in nfvPPA patients.6,7 Repetitive 
transcranial magnetic stimulation (rTMS) is a method used to modulate brain plas-
ticity and is increasingly being used in the therapy of neurological and psychiatric 
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disorders.8 In this technique, trains of brief, time-varying 
magnetic field pulses are delivered from a coil placed over 
the selected cortical area, which induces an electrical field 
within neural tissue and repetitively excites neurons. System-
atic stimulation over subsequent days is capable of changing 
the activity of the stimulated brain area and induces clinical 
effects that last for weeks or months.9 In the area of disorders 
associated with dementia, such as Alzheimer’s disease (AD) 
or dementia with Lewy bodies, rTMS has shown promising 
results in alleviating neuropsychiatric symptoms and improv-
ing cognitive deficits.9 The aim of the present study was to 
assess whether rTMS could also have therapeutic potential 
in the population of patients suffering from FTD.
Materials and methods
study design and subjects
This was an open-label study involving 2 weeks of rTMS. 
The study was performed according to the Declaration of 
Helsinki of 1975 for Human Research and the protocol was 
approved by the Bioethics Committee of the Jagiellonian Uni-
versity (permission number 122.6120.178.2015). All subjects 
gave their written informed consent prior to inclusion.
The study included patients with all variants of FTD. 
They met the criteria for probable bvFTD10 or for the clinical 
diagnosis of nfvPPA or SV-PPA.11 The criteria for probable 
bvFTD included the presence of three out of six neurop-
sychological features: disinhibition, apathy/inertia, loss of 
sympathy/empathy, perseverative/compulsive behaviors, 
hyperorality, and dysexecutive neuropsychological profile, 
as well as radiological abnormalities in the frontal and/or 
anterior temporal lobes, which, depending on technique, 
should indicate atrophy, hypoperfusion, or hypometabolism. 
The clinical diagnosis of nfvPPA required the presence of 
agrammatism or speech apraxia and two out of three other 
features: impaired comprehension of complex sentences, 
spared single-word comprehension, and spared object 
knowledge. The criteria for the clinical diagnosis of SV-PPA 
included impaired confrontation, naming and single-word 
comprehension, and the presence of three of the following 
features: impaired object knowledge, surface dyslexia or 
dysgraphia, spared repetition, and spared speech production. 
To be included, patients with nfvPPA and SV-PPA were 
required additionally to show generalized cognitive decline 
reflected by an abnormal score on the Montreal Cognitive 
Assessment (MoCA). A further inclusion criterion was an 
age between 40 and 80 years. Also required was the presence 
of a caregiver who was responsible for the patient’s adher-
ence to therapy and capable of assessing potential changes 
in the patient’s daily function. Neuroimaging was carried 
out no earlier than 2 years prior to inclusion. Exclusion 
criteria included neuropsychiatric symptoms or cognitive 
deficits suggestive of pathology other than frontotemporal 
lobar degeneration, treatment with memantine or other 
procognitive agents, and the presence of contraindications 
to rTMS as listed by the Safety of TMS Consensus Group 
of the International Federation of Clinical Neurophysiol-
ogy (IFCN).12
We recruited 11 patients (seven women and four men) 
with a mean age of 61.7±10.1 years. Nine of them were diag-
nosed with bvFTD, one with nfvPPA, and one with SV-PPA. 
Three patients were mildly depressive (baseline Hamilton 
Depression Rating Scale [HDRS] 8–16) and one was severely 
depressive (HDRS$24). The demographic and clinical data 
of the investigated group are summarized in Table 1.
Table 1 Demographic and clinical data of the recruited patients
Gender Age 
(years)
Education (years) Diagnosis Disease duration (years) MoCA at 
baseline
HDRS at 
baseline
M 58 17 bvFTD 2 23 4
F 53 17 bvFTD 5 21 24
F 64 17 bvFTD 5 20 13
F 72 21 bvFTD 2 18 0
M 68 17 bvFTD 1 23 5
M 43 13 bvFTD 3 25 14
F 64 12 bvFTD 2 12 13
M 65 17 bvFTD 6 26 0
F 70 13 nfvPPa 2 9 4
F 48 14 sV-PPa 1 17 0
F 74 10 bvFTD 7 18 0
Mean (n=7 F) 61.7 15.3 3.3 19.3 7
sD (n=4 M) 10.1 3.1 2.1 5.3 7.9
Abbreviations: M, male; F, female; Moca, Montreal cognitive assessment; hDrs, hamilton Depression rating scale; bvFTD, behavioral variant of frontotemporal dementia; 
nfvPPA, nonfluent/agrammatic variant primary progressive aphasia; SD, standard deviation; SV-PPA, semantic variant-primary progressive aphasia.
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intervention
rTMS at a frequency of 10 Hz was delivered over the bilat-
eral dorsolateral prefrontal cortex (DLPFC), defined as a 
point 7 cm anterior to the hotspot area for the left and right 
abductor digiti minimi (ADM). The hotspot was determined 
as an area on the scalp where the magnetic stimuli could 
produce the greatest motor evoked potentials (MEPs) from 
ADM. Stimulation intensity was 90% of the resting motor 
threshold (RMT) or, if the patient could not fully relax the 
hand musculature, 90% of the active motor threshold (AMT). 
RMT and AMT were determined according to the relative 
frequency method, described by the IFCN.13 According to 
this, RMT is the lowest intensity of magnetic field capable 
of evoking MEPs of amplitude $50 μV after at least five of 
10 stimuli in the hotspot and from the relaxed muscle. For 
AMT, the amplitude required is $200 μV and the muscle 
is slightly contracted. The whole intervention included 
10 sessions, delivered in one session per day, on 10 con-
secutive working days. In every session, 1,500 pulses were 
delivered to each DLPFC (in total 3,000 pulses per session) 
divided into 20 trains, each containing 75 pulses, separated 
by 25 s intervals. Stimulation was done with a double 70-mm 
air-cooled figure-of-eight coil with a peak magnetic field of 
0.93 T and with the Magstim Rapid2 stimulator (Magstim 
Company, Whitland, UK). Medication for neuropsychiatric 
symptoms remained unchanged several weeks before and 
during the intervention.
Outcome measures
Before and after rTMS, patients underwent assessment with 
the Clinical Global Impression-Improvement,14 the 21-item 
HDRS,15 and the Geriatric Depression Scale (GDS).16 Fron-
tal deficits were investigated with the Frontal Assessment 
Battery (FAB),17 a test which consists of six subsets related 
to the mental processes of conceptualization and abstract 
reasoning, mental flexibility, motor programming and 
executive control of action, resistance to interference, self-
regulation, inhibitory control, and environmental autonomy. 
The performance in each subset was rated between 0 and 
3. The final result is the summation of the subscores of the 
subsets, with lower scores indicating more severe frontal 
deficits.
Overall cognitive performance was assessed with the 
Polish version of the MoCA.18 The MoCA is a test originally 
developed to detect mild cognitive impairment, which was 
later adopted to evaluate cognitive impairment in early 
AD,19 Parkinson’s disease,20 and other diseases. The test 
features 30 points, which collectively assess performance 
in seven cognitive domains: visuospatial/executive, naming, 
attention, language, abstraction, delayed recall, and orienta-
tion. A lower summarized score indicates worse cognitive 
performance and the cut-off indicating cognitive impairment 
is ,26.18
Further assessment included the Stroop Color – Word 
Test, which consists of three stages. First, patients read the 
names of colors written in black ink as quickly as possible; 
second, they name the colors of printed rectangles. Finally, 
patients are required to read a list of the names of colors 
from the first stage, but written in incongruent ink colors. 
The time taken to perform these tasks is scored along with 
the number of errors.21
Patients also underwent the Letter Cancellation Test (LCT) 
and the Digit Cancellation Test (D-CAT), two tools used to 
assess sustained attention. The LCT consists of a page with 
170 letters of the Latin alphabet printed randomly, with even 
spaces between letters. The subjects are instructed to cross 
out the letters E and R as quickly as they can. The final result 
takes into consideration the number of correctly crossed-out 
letters, the number of incorrectly crossed-out letters, and the 
time taken to complete the test.22 In D-CAT, subjects should 
cancel the digits 2 and 8 among one to nine randomly printed 
digits. The evaluation is similar to the LCT.23
Finally, the subjects performed the Verbal Fluency 
Test.24 In the first part of this test, they were given 60 s to 
say as many words beginning with the letter S or F as they 
could. In the second part, the same amount of time was given 
to say the names of as many animals or fruits as possible.
The caregiver’s impression of patient function was rated 
with the Polish version of the Frontal Behavioral Inventory 
(FBI).25 The FBI evaluates frontal behavioral deficits via 
an interview with the caregiver and consists of 24 items 
grouped in two subscales. The first of these subscales 
measures negative symptoms and the second disinhibition 
symptoms. Items are rated from 0 to 3, where 3 implies a 
more severe behavioral disorder. Baseline and posttreatment 
measurements were performed on the days of the first and 
last sessions, respectively.
statistics
Measurements taken before and after rTMS were compared 
using the two-tailed Wilcoxon signed-rank test. Consider-
ing our interest in the outcome of all cognitive domains that 
may be affected in FTD, and our intention to avoid excessive 
type II errors in this small and explorative study, we decided 
not to employ a correction for multiple comparisons. Calcu-
lations were made with the Statistica data analysis software 
system, version 12.0 (StatSoft, 2008; Palo Alto, CA, USA). 
The significance level was set to p,0.05.
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Results
A few patients complained of pain during rTMS at the site of 
stimulation, which resolved by the second or third session. 
One patient (female, 64 years of age) suffered from mild, 
diffused headache, persisting for 2–3 months after rTMS, 
which she attributed to the stimulation. There were no other 
side effects. Mean motor threshold (AMT in one patient 
and RMT in the rest), averaged for both hemispheres, was 
73%±17%. FBI was not performed in one patient (female, 
64 years of age).
After rTMS, there was improvement in the total score 
of MoCA as well as in the domains of visuospatial abilities 
and abstraction. In the D-CAT and LCT, there were fewer 
omissions; the time was shortened in the latter. In both tests, 
the number of commission errors could not be statistically 
compared owing to the low number of degrees of freedom. 
This was also the case for the number of errors in the Stroop 
reading test; however, in this test, performance time was 
shortened. In Stroop Color naming, the number of errors 
was reduced and the FBI score was reduced. Other tests and 
questionnaires showed no changes. The detailed data of 
measurements acquired before and after rTMS are presented 
in Table 2. Two patients with mild depression improved to 
normal status in terms of HDRS score. A third patient with 
mild depression remained with the same diagnosis (a change 
in HDRS from 13 to 12 points). One patient with severe 
depression showed a reduction in HDRS, allowing us to clas-
sify him as mildly depressive (a change from 24 to 12 points). 
Two patients (both women, aged 72 and 48 years) showed an 
increase in HDRS score after rTMS, one from 0 to 2 and the 
other from 0 to 4. GDS was abnormal in three cases showing 
mild depression (10–19 points). Five patients improved, two 
remained unchanged, and four deteriorated after rTMS.
Owing to the high prevalence of patients with bvFTD, 
calculations were repeated after the exclusion of two patients 
with nfvPPA and SV-PPA. This post hoc analysis showed an 
increase in MoCA total score (20.7±4.3 vs 22.4±5.2, T=3, 
p=0.036) and in the domain of visuospatial abilities (3.0±1.3 
vs 3.8±1.1, T=0, p=0.043). There were fewer omissions in 
LCT (6.0±7.3 vs 2.4±2.9, T=3, p=0.021). In the Stroop test, 
the time for color naming and for interference shortened 
(36.7±16.1 vs 33.4±12.8 s, T=4, p=0.049951 and 91.9±59.2 
vs 86.7±57.1 s, T=1, p=0.017, respectively). Scores on the 
FBI also decreased (32.8±14.5 vs 25.1±13.5 s, T=0, p=0.012). 
Other measurements showed no changes.
Discussion
To the best of our knowledge, this is the first report to 
investigate the efficacy of rTMS in improving the cognitive 
and neuropsychiatric symptoms of FTD. Two previous case 
reports described an improvement in the language function of 
patients with PPA; however, these did not disclose whether 
the syndrome was related to FTD.26,27 Moreover, our study 
appears to be one of the first studies to report cognitive 
improvement in FTD. Apart from the previously mentioned 
studies with tDCS,6,7 there was only one other study, in 
which oxytocin improved social, but no other aspects of 
cognition.28 In this light, the improvements achieved in 
the significant part of tests used in our study may be seen 
as outstanding compared to previously published results. 
The MoCA improvement of nearly 2 points is similar to 
that seen in one randomized controlled trial for rTMS in 
AD,29 which showed a significant difference compared to 
a placebo. On the other hand, there was less improvement 
than in another study of AD patients, in which the level of 
improvement was 4.21±2.46 points.30 In the previous study, 
Table 2 results of particular tests before and after rTMs
Test Before 
rTMS
After 
rTMS
T p-value
Mean SD Mean SD
cgi-i 4.0 1.7 2.8 0.6 3 0.934
Domains of Moca 2.8 1.3 3.6 1.1 0 0.018*
visuospatial/executive
Naming 2.4 1.0 2.4 0.9 5 1.000
attention 4.0 2.4 4.0 1.8 18 1.000
language 1.5 1.1 1.9 1.3 0 0.109
abstraction 1.0 0.8 1.5 0.7 0 0.043*
Delayed recall 1.9 2.0 2.0 2.0 6 0.686
Orientation 5.5 1.2 5.5 1.2 1.5 1.000
Moca total score 19.3 5.3 21.1 5.8 3 0.013*
D-caT
Time 88.6 20.7 85.1 19.4 22 0.328
Omissions 6.1 4.0 4.7 3.7 7.5 0.023*
lcT
Time 79.4 13.1 73.8 13.3 9 0.033*
Omissions 7.8 7.7 3.9 4.3 3 0.008*
stroop reading time 27.4 8.6 25.7 8.5 8 0.047*
stroop color naming time 43.2 21.5 43.7 28.3 20.5 0.476
errors 3.1 4.2 1.1 2.0 0 0.028*
stroop interference time 97.1 58.2 113.8 79.1 11 0.093
errors 7.5 11.7 5.0 6.2 5 0.069
FaB 12.1 4.5 13.2 4.1 10 0.074
VFT
Formal fluency 7.5 5.3 9.3 6.1 4 0.091
Semantic fluency 11.5 7.1 12.0 6.1 24.5 0.450
gDs 4.8 4.2 4.8 4.1 22.5 1.000
hDrs 7.0 7.9 3.8 4.3 8 0.161
FBi 33.6 13.4 26.2 12.3 0 0.005*
Note: *Significant difference (p,0.05).
Abbreviations: rTMs, repetitive transcranial magnetic stimulation; sD, standard 
deviation; T, test value; cgi-i, clinical global impression-improvement; Moca, 
Montreal cognitive assessment; D-caT, Digit cancellation Test; lcT, letter 
cancellation Test; FaB, Frontal assessment Battery; VFT, Verbal Fluency Test; gDs, 
geriatric Depression scale; hDrs, hamilton Depression rating scale; FBi, Frontal 
Behavioral inventory.
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however, the stimulation (1 Hz to the right DLPFC) included 
20 sessions, which is twice as many as the number used in 
our present study. The observed improvement appears not 
to differ from other trials of rTMS in dementia in terms of 
cognitive function which responded to therapy. Most studies 
have reported improvement in scales measuring general 
cognitive status and in many other functions, of which some, 
such as attention and memory, also showed improvement in 
our group.9 It remains unclear whether the effect of rTMS 
on cognition in dementia results from an influence on the 
underlying neurodegenerative process or from the nonspe-
cific enhancement of frontal activity. Several studies have 
reported improvements in various cognitive functions after 
rTMS, or other noninvasive brain stimulation techniques, 
applied to frontal areas in healthy individuals, which would 
allow us to attribute the beneficial effects observed in patients 
to nonspecific neuroenhancement.31 On the other hand, the 
results are different in other diseases where cognitive impair-
ment is linked to symptoms: in schizophrenia no effect of 
rTMS on cognition was found,32 and in depression, it was 
modest and limited to specific functions of psychomotor 
speed, visual scanning, and set-shifting ability.33
Considering the possibility that our results may have 
been influenced by a learning effect, we carried out a review 
of the appropriate literature. In healthy older volunteers, a 
learning effect was described for the Stroop test over an 
interval of 5.7 days between two subsequent tests,34 which 
is significantly shorter than in our study. The MoCA per-
formed after 60 min,35 or after 1 month,36 did not show a 
significant learning effect in healthy individuals. Similarly, 
placebo groups in other studies investigating the efficacy of 
rTMS in dementias did not show an improvement on either 
MoCA29,30 or Stroop.37 Thus, in our opinion, the learning 
effect is unlikely to explain the obtained results, although it 
needs to be definitely excluded using a sham comparator.
Another concern may have arisen from the lack of cor-
rection for multiple comparisons; as a consequence, some 
of the significant differences among our results may have 
occurred by chance. However, we would like to highlight 
that while the number of tests performed on the whole group 
(24) generally increases the risk of false rejection of the null 
hypothesis, the number of significant differences detected 
(nine) makes it improbable that all of these differences are 
accidental and do not reflect the association between inter-
vention and improvement. We did not take into account the 
repetition of the analysis on the sample limited to bvFTD as 
the tests performed on nearly the same data were unlikely 
to increase the chance of additional, significant differences. 
In our opinion, using a correction in such an exploratory and 
small study would increase the risk of type II errors too much. 
This lack of correction may have influenced our results in 
respect of the number of cognitive domains that responded 
to therapy, but was very unlikely to have affected our main 
conclusion that rTMS may have potential in the therapy of 
cognitive impairment in patients with FTD.
Contrary to expectations, cognitive improvement was 
not followed by an antidepressive effect. This result may 
have been due to the relatively low rate of patients with 
abnormal HDRS. On the other hand, the study by Schaller 
et al,38 describing improvements of mood in healthy indi-
viduals after rTMS, led us to expect a reduction in HDRS 
and GDS in our patients. We speculate that greater aware-
ness of the disease, which may occur along with cognitive 
improvement, could account for the lack of an antidepressive 
effect. Another reason may lie in our rTMS protocol, which 
involved high-frequency stimulation of the right DLPFC, 
which, in turn, may account for the deterioration in the mood 
of several participants. One previous case report reported that 
high-frequency stimulation over the right DLPFC induced an 
increase in the Montgomery–Åsberg Depression Rating Scale 
from 7 to 21 points.39 Such a stimulation protocol was also 
tried to alleviate bipolar mania, with some studies reporting 
a significant effect.40,41 In terms of other results, the reduc-
tion in FBI score may positively influence the caregiver’s 
quality of life, which is often severely affected, resulting in 
significant changes to social and family life.42 To the best of 
our knowledge, only two previous studies have reported a 
reduction in FBI score after intervention.28,43
The explanation of our results relies on several, only par-
tially verified hypotheses pertaining to how rTMS may influ-
ence cerebral function. At the cellular level, repetitive neural 
excitation changes synaptic and plasmalemmal excitability 
and upregulates growth factors.44 In animal models, previous 
research has shown that rTMS affects the mRNA transcript 
of particular genes in neural cell cultures.45 Cellular changes 
thus lead to the modification of excitability and metabolic 
activity of targeted cortical areas as well as inducing synaptic 
plasticity.8 We chose the prefrontal areas as the target of 
stimulation because previous studies showed that these areas 
are behaviorally involved in a variety of cognitive opera-
tions, including working and episodic memory, inhibition, 
monitoring, strategic organization, and planning.46 Moreover, 
previous data indicate that stimulation over the DLPFC can 
improve language function,47 attention, memory, and other 
cognitive functions in healthy volunteers.48 Finally, we 
investigated other rTMS studies on patients with dementias 
involving frontal areas and related cognitive deficits. In these 
previous studies, rTMS was most commonly delivered over 
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the bilateral DLPFC.9 Similarly, our relatively weak stimula-
tion intensity was based on previous experience and on the 
premise that cognitively and behaviorally impaired patients 
could not adhere to stronger pulses, which, in some cases, 
may induce mild to moderate pain.12 Despite our concerns, 
the adherence to and attitude toward therapy were very good 
among our patients and caregivers, and only mild pain was 
reported. In our opinion, future studies on dementias could 
attempt suprathreshold stimulation, which is often used in 
other conditions, such as depression.8
In the present study, we investigated patients with all 
subtypes of FTD. The large proportion of patients with 
bvFTD allowed a post hoc analysis of this subgroup, which 
showed similar effects to those for all patients.
limitations
We are aware of the preliminary character of this study, which 
lacks a placebo arm and follow-up. Moreover, determination 
of the stimulation point in relation to the motor hotspot, 
instead of using one of the available neuronavigation systems, 
could have caused minor deviation from the actual DLPFC. 
Finally, the inclusion of patients with concomitant depres-
sion could have confounded the results toward a reduction of 
cognitive enhancement, as previous data showed very limited 
effects on cognition among depressive patients.33
Conclusion
rTMS is safe and well tolerated in FTD patients. The out-
comes of this study indicate that this technique may improve 
cognitive performance in this group of patients. The results of 
the FBI further suggest that rTMS may also improve daytime 
functioning, with potential benefit for caregivers. The data 
obtained in this study warrant randomized controlled trials 
on this subject.
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